Effect of a CCK-1R Agonist on Food Intake in Humans
The ultimate aim of this study is to test the hypothesis that the oral cholecystokinin (CCK) agonist GSKI181771X will reduce the size of a binge meal among individuals with Bulimia Nervosa. The study will be conducted in phases. First, an effective dose for reducing food intake, when normal subjects eat normally will be attained. Next, it will be determined whether intake at this dose is reduced in control subjects instructed to eat to capacity. If the dose is still effective compared to placebo, the same dose will be tested in patients with bulimia nervosa.
100 项与 GW-181771 相关的专利(医药)
2005-01-01·Folia Pharmacologica Japonica
医薬品開発における放射性薬剤の利用:極微量(microdose)投与後の薬物動態のAMSおよびPETによる評価